Hims & Hers Health, Inc. (HIMS) Stock: Price, Forecast & Analyst Target
Hims & Hers Health, Inc. (HIMS) — MoonshotScore 33/100 (Weak band), calculated Oct 5, 2026. Price $29.67 (+2.31%), as of the Oct 5, 2026 trading session; market cap $6.62B. Expected results Nov 9, 2026.
Educational signal · not a buy or sell recommendation · How to read this
Market value / cash and short-term investments: 7.87× (market value Oct 5, 2026; cash Jun 30, 2026) · expected results Nov 9, 2026
Hims & Hers Health, Inc. · HIMS · NYSE · Healthcare · Medical - Care Facilities
Research dated 2026-09-13: The company operates a telehealth platform connecting patients with licensed clinicians for prescriptions and over-the-counter wellness products. Profitability has vanished in the most recent quarters despite sustained revenue growth, and the question is whether this signals a structural problem with unit economics or a temporary squeeze that resolves as the platform scales.
Price as of Oct 5, 2026
Key Statistics
MoonshotScore v2 · Hims & Hers Health (HIMS)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
High quality and durable growth, but a fragile balance sheet. Business Quality: Solid; Financial Safety: Fragile; Valuation: Full; Growth Durability: Growing; Momentum: Quiet.
- quarterly revenue $753M (Q2 FY2026, quarter ended Jun 2026)
- EPS beat 4 of 8
- Altman Z 1.59 · Piotroski F 2
Holding back: balance-sheet strain
Helping: business quality, durable growth
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 33 | Weak | |
| 33 | Weak | |
| 33 | Weak | |
| 33 | Weak | |
| 33 | Weak | |
| 33 | Weak |
The score was 33 in the stored Oct 4, 2026 snapshot and remains 33 in the current publication computed Oct 5, 2026 (0).
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · Educational signal · not a buy or sell recommendation · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $29.67 | |
| Change on the day | +2.31% | |
| 52-week range | $13.74 – $65.30 | |
| Market capitalisation | $6.62B | |
| Price / earnings (trailing) | 50.00 | |
| Shares traded on the day | 7.97M | |
| Beta (volatility vs the S&P 500) | 2.41 |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · below the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · below the recorded estimate
- · Earnings results · below the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
The provider's estimated date can change.
What to watch nextOther perspectives
Council score for Hims & Hers Health (HIMS): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
6 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Oct 1, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 19, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 19, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Oct 6, 2026, except a card that shows its own read date.
Watch the HIMS film — every key number, told as a short cinematic story
~2 min · open the film
What is Hims & Hers Health (HIMS), and what does it report?
Short answer · as of
The platform generates revenue from virtual consultations billed to insurance and patient copays alongside direct-to-consumer sales of medications and wellness products.
Research dated 2026-09-13.
The platform generates revenue from virtual consultations billed to insurance and patient copays alongside direct-to-consumer sales of medications and wellness products. The reporting combines these into aggregate revenue, making it difficult for investors to isolate high-margin consultations from lower-margin product sales.
The company carries substantial debt while operating at gross margins typical of commodity retail.
What do the latest results show for Hims & Hers Health (HIMS)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of $753M.
Research dated 2026-09-13.
The most recent quarter showed operating losses widen even as revenue accelerated, meaning incremental sales generated less operating profit than the prior period. Selling and general expenses contracted as a percentage of revenue, but research and development expense rose, suggesting the company is investing in competitive differentiation while profitability deteriorates.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
- Latest quarter · revenue
- $753.21M Jun 30, 2026
- Latest quarter · SG&A
- $427.61M Jun 30, 2026
- Latest quarter · FMP standardized operating result
- −$97.19M Jun 30, 2026
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Jun 30, 2026 | $753.21M | Not available | $427.61M | −$97.19M |
| Mar 31, 2026 | $608.10M | $46.94M | $331.67M | −$16.47M |
| Dec 31, 2025 | $617.82M | $40.96M | $314.21M | $9.19M |
| Sep 30, 2025 | $598.98M | $40.58M | $312.83M | $11.81M |
USD. The operating result is the FMP-standardized value supplied by FMP; it may differ from a filing’s GAAP loss from operations when the provider classifies separately presented items differently. It is not net income or cash flow.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $753.21M Aug 10, 2026
- Latest report · revenue estimate
- $698.90M Aug 10, 2026
- Latest report · revenue vs estimate
- Above estimate Aug 10, 2026
- Latest report · EPS vs estimate
- Below estimate Aug 10, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Aug 10, 2026 | $753.21M | $698.90M | −$0.3700 | −$0.0498 |
| May 11, 2026 | $608.10M | $616.84M | −$0.4000 | $0.0254 |
| Feb 23, 2026 | $617.82M | $619.23M | $0.0700 | $0.0200 |
| Nov 3, 2025 | $598.98M | $618.05M | $0.0600 | $0.0900 |
Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $753M | -$86M | -$0.37 (diluted) |
| Q1 FY2026 | $608M | -$92M | -$0.40 (diluted) |
| Q4 FY2025 | $618M | $21M | $0.08 (diluted) |
| Q3 FY2025 | $599M | $16M | $0.06 (diluted) |
What are the financial strengths and risks for Hims & Hers Health (HIMS)?
Short answer
Cash and short-term investments were $841.05M at the Jun 30, 2026 balance-sheet date. Operating cash flow was −$35.94M for the quarter ended Jun 30, 2026, meaning operations used cash. These figures do not establish a cash runway.
Research dated 2026-09-13.
Gross margins remain robust, providing cushion for operating expenses, but the balance sheet shows liquidity metrics that fall short of prudent standards and leverage ratios that exceed comfortable thresholds, meaning the company has limited liquid assets to cover near-term obligations if revenue stalls.
The most pressing risk is that revenue growth masks deteriorating unit economics in customer acquisition or retention.
Data-derived red flags
- Financial-distress signal — its Altman Z-Score of 1.59 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-30.0%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
How much cash does the business generate or use?
Quarterly operating cash flow shows cash generated or used by operations.
- Latest quarter · operating cash flow
- −$35.94M Jun 30, 2026
- Previous quarter · operating cash flow
- $89.36M Mar 31, 2026
| Period end | Operating cash flow | Capital expenditure (reported) |
|---|---|---|
| Jun 30, 2026 | −$35.94M | −$19.45M |
| Mar 31, 2026 | $89.36M | −$36.32M |
| Dec 31, 2025 | $64.70M | −$63.88M |
| Sep 30, 2025 | $148.72M | −$57.30M |
Operating cash-flow bars share one scale and show magnitude; negative values mean cash used.
USD. Negative operating cash flow means cash used. Capital expenditure keeps the provider’s reported sign; it is not added here to estimate free cash flow or runway.
What should you watch next at Hims & Hers Health (HIMS)?
Short answer · as of
The next earnings report is expected on Nov 9, 2026.
Research dated 2026-09-13.
Insiders have sold continuously over the most recent period with no offsetting purchases, which typically signals weak conviction about near-term recovery. Watch whether the next reported quarter returns to profitability or the loss persists, because sustained operating losses would suggest recent earnings swings are not seasonal noise.
How does Hims & Hers Health compare with its peers?
Short answer
Hims & Hers Health's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-13.
Most digital health platforms operate under the same margin and cash-consumption trade-off: either they push through to profitability by cutting customer acquisition spending, or they accelerate acquisition and defer profits. Hims is distinctive in its exposure to over-the-counter product sales, which are lower margin than prescription services but can build retail loyalty. That mix is unique among telehealth peers and represents the company's strategic differentiation.
| Company | Price | Market value | Score |
|---|---|---|---|
| $230.37 Oct 5, 2026 | $3.60B | 98 5-pillar Oct 5, 2026 | |
| $317.11 Oct 5, 2026 | $12.5B | 95 5-pillar Oct 5, 2026 | |
| $176.05 Oct 5, 2026 | $10.7B | 94 5-pillar Oct 5, 2026 | |
| $12.22 Oct 5, 2026 | $4.74B | 93 5-pillar Oct 5, 2026 | |
| $120.97 Oct 5, 2026 | $12.0B | 90 5-pillar Oct 5, 2026 | |
| $511.30 Oct 5, 2026 | $6.68B | 87 5-pillar Oct 5, 2026 | |
| $140.65 Oct 5, 2026 | $9.98B | 83 5-pillar Oct 5, 2026 | |
| $22.65 Oct 5, 2026 | $12.0B | 83 5-pillar Oct 5, 2026 | |
| $23.37 Oct 5, 2026 | $3.50B | 81 5-pillar Oct 5, 2026 | |
| $172.89 Oct 5, 2026 | $10.1B | 75 5-pillar Oct 5, 2026 | |
| $178.72 Oct 5, 2026 | $11.5B | 75 5-pillar Oct 5, 2026 | |
| $57.54 Oct 5, 2026 | $11.1B | 65 5-pillar Oct 5, 2026 | |
| Hims & Hers Health (HIMS) — this page | $29.67 | $6.62B | 33 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $24.50 – $42.00
- Consensus target
- $32.17
- Median target
- $32.00
Consensus record · Captured .
Measured against a quoted price of $29.67 (as of Oct 5, 2026).
Insider activity
Form 4 records via FMP · Of the newest 60 records, those within the last 180 days, newest dated Oct 1, 2026
- Transactions
- 60
- Identified insiders
- 9
- Purchases
- 0
- Sales
- 13
- Other transactions
- 47
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
- Institutional ownership
- 69.3% Period end Jun 30, 2026
- Previous quarter · ownership
- 65.4% Prior to period end Jun 30, 2026
- Reporting holders
- 586 Period end Jun 30, 2026
- Previous quarter · holders
- 490 Prior to period end Jun 30, 2026
| Holders in provider snapshot | Shares |
|---|---|
| Blackrock, INC. | 28,703,514 |
| Susquehanna International Group, Llp | 13,539,700 |
| Vanguard Portfolio Management LLC | 10,559,314 |
| Vanguard Capital Management LLC | 9,541,384 |
| Susquehanna International Group, Llp | 9,004,900 |
Quarterly filings lag the period end. Holder rows are names in the provider snapshot, not a verified ranking; individual filing dates are not supplied. Related managers may appear separately, so these positions are not summed. Holder snapshot as of Jun 30, 2026.
What has been published about Hims & Hers Health (HIMS)?
- 4 Health Care Stocks With Whale Alerts In Today’s Session
- 10 Health Care Stocks With Whale Alerts In Today’s Session
- INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Hims & Hers Health, Inc. of Class Action Lawsuit and Upcoming Deadlines – HIMS
- Kaplan Fox Encourages Hims & Hers Health, Inc. (HIMS) Investors Seeking Recovery to Contact the Firm Before November 2, 2026
Hims & Hers Health Healthcare Stock: Key Questions Answered
Research dated 2026-09-13; the answers below are from that research, and the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
How does Hims make money from sexual health and hair care products?
These are over-the-counter categories sold directly through the platform alongside prescription consultations, expanding the customer's lifetime value by creating additional purchasing occasions. The company's portfolio combines recurring prescription revenue with non-recurring product sales.
What does the recent insider selling tell us?
Over the most recent period, insiders have executed net sales with no corresponding purchases, with the heaviest activity occurring most recently. This pattern typically reflects either tax-motivated rebalancing or loss of conviction about near-term stock recovery. Insiders who are confident in the business trajectory typically maintain consistent ownership levels.
Why did profitability evaporate in the latest quarters even as revenue accelerated?
Operating expenses remain partially fixed, and the most recent periods saw elevated spending on research and development alongside continued deployment of sales and marketing infrastructure. The deterioration suggests the company prioritized market position over near-term earnings, betting that scale will eventually drive margin improvement.
Is the balance sheet stable enough to support current revenue trajectory?
Liquid assets cover less than would be required for an extended revenue decline, while total debt exceeds liquid resources significantly, meaning the company relies on sustained cash generation from operations. A sharp downturn in revenue growth would force the company to issue equity or cut spending, both dilutive to current shareholders.
What is the HIMS stock price today?
The last price recorded on this page for Hims & Hers Health, Inc. (HIMS) is $29.67, as of the Oct 5, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the HIMS price target?
The analyst consensus price target for Hims & Hers Health, Inc. (HIMS) is $32.17 (range $24.50 to $42.00, median $32.00), per FMP data captured Oct 5, 2026. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Research written by Claude (claude-haiku-4-5) on 2026-09-13. AI-authored analysis; source dates are shown with each answer. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (81 figures)
The 81 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
OFFICIAL — 1 fact from SEC filings and earnings calls
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
id.hq | SEC filing business address | 2269 Chestnut ST, #523, SAN Francisco, CA, 94123 | OFFICIAL | SEC EDGAR filer business address — The SEC filer business address. Our market-data provider separately lists "2269 Chestnut Street, San Francisco, CA, 94123, US". |
FMP — 71 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
earn.next | Next earnings date | Nov 9, 2026 | FMP | Financial Modeling Prep (FMP) earnings calendar — The date is our provider's estimate until the company confirms it. | |
px.last | Latest provided price | $29.67 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-05T21:54:37.999Z. | |
px.change | Change on the day | +2.31% | FMP | Financial Modeling Prep (FMP) · quote | |
px.mcap | Market capitalisation | $6.62B | FMP | Financial Modeling Prep (FMP) · quote — Date unknown Market cap record date: 2026-10-05. FMP quote timestamp: 2026-10-05T20:00:03.000Z. Captured from FMP at 2026-10-05T21:54:37.065Z. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares. | |
px.change_abs | Change on the day, in dollars | +$0.67 | FMP | Financial Modeling Prep (FMP) · quote | |
fin.q_revenue | Revenue, Q2 FY2026 | $753M | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
px.pe | Price / earnings (trailing) | 50.00 | FMP | Financial Modeling Prep (FMP) · quote | |
px.volume | Shares traded on the day | 7.97M | FMP | Financial Modeling Prep (FMP) · quote | |
px.beta | Beta | 2.41 | FMP | Financial Modeling Prep (FMP) company profile | |
id.ceo | Chief executive | Andrew Dudum | FMP | Financial Modeling Prep (FMP) key executives (proxy-derived) — Titles and pay come from the company's proxy statement as our provider parsed it. | |
id.employees | Employees | 2,442 | FMP | Financial Modeling Prep (FMP) employee count, from the company's filing | |
fin.annual | Revenue and net result by fiscal year | 5 fiscal years, FY2021 through FY2025: FY2021 revenue $271.88M, net result −$107.66M; FY2022 revenue $526.92M, net result −$65.68M; FY2023 revenue $872.00M, net result −$23.55M; FY2024 revenue $1.48B, net result $126.04M; FY2025 revenue $2.35B, net result $128.37M | FMP | Financial Modeling Prep (FMP), from the company's 10-K income statements | |
fin.gross_margin | Gross margin (trailing twelve months) | 64.7% | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm — A ratio our provider could not compute is absent rather than shown as zero. | |
fin.q_table.depth.2026-06-30.revenue_k | Revenue — period end 2026-06-30 | $753.21M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-06-30.sga_k | SG&A — period end 2026-06-30 | $427.61M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-06-30.operating_result_k | FMP standardized operating result — period end 2026-06-30 | −$97.19M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-31.revenue_k | Revenue — period end 2026-03-31 | $608.10M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-31.rd_k | R&D — period end 2026-03-31 | $46.94M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-31.sga_k | SG&A — period end 2026-03-31 | $331.67M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-31.operating_result_k | FMP standardized operating result — period end 2026-03-31 | −$16.47M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.revenue_k | Revenue — period end 2025-12-31 | $617.82M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.rd_k | R&D — period end 2025-12-31 | $40.96M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.sga_k | SG&A — period end 2025-12-31 | $314.21M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.operating_result_k | FMP standardized operating result — period end 2025-12-31 | $9.19M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-30.revenue_k | Revenue — period end 2025-09-30 | $598.98M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-30.rd_k | R&D — period end 2025-09-30 | $40.58M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-30.sga_k | SG&A — period end 2025-09-30 | $312.83M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-30.operating_result_k | FMP standardized operating result — period end 2025-09-30 | $11.81M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
earn.history.depth.2026-08-10.revenue_actual | Revenue · reported — report date 2026-08-10 | $753.21M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-08-10.revenue_estimated | Revenue · estimate — report date 2026-08-10 | $698.90M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-08-10.eps_actual | EPS · reported — report date 2026-08-10 | −$0.3700 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-08-10.eps_estimated | EPS · estimate — report date 2026-08-10 | −$0.0498 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-11.revenue_actual | Revenue · reported — report date 2026-05-11 | $608.10M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-11.revenue_estimated | Revenue · estimate — report date 2026-05-11 | $616.84M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-11.eps_actual | EPS · reported — report date 2026-05-11 | −$0.4000 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-11.eps_estimated | EPS · estimate — report date 2026-05-11 | $0.0254 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-23.revenue_actual | Revenue · reported — report date 2026-02-23 | $617.82M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-23.revenue_estimated | Revenue · estimate — report date 2026-02-23 | $619.23M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-23.eps_actual | EPS · reported — report date 2026-02-23 | $0.0700 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-23.eps_estimated | EPS · estimate — report date 2026-02-23 | $0.0200 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-03.revenue_actual | Revenue · reported — report date 2025-11-03 | $598.98M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-03.revenue_estimated | Revenue · estimate — report date 2025-11-03 | $618.05M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-03.eps_actual | EPS · reported — report date 2025-11-03 | $0.0600 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-03.eps_estimated | EPS · estimate — report date 2025-11-03 | $0.0900 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
fin.q_table | Quarterly income statement | 4 quarters through Q2 FY2026 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed | |
fin.cash_investments | Cash and short-term investments | $841.05M | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. Long-term investments are excluded and remain unclassified. Restrictions on cash and short-term investments require separate review. | |
fin.opcf_latest | Latest-quarter operating cash flow | −$35.94M | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Period end: 2026-06-30. Negative operating cash flow means cash used. This figure is not a cash-runway estimate. | |
fin.long_term_investments | Long-term investments (classification unverified) | $0.00 | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | |
fin.total_debt | Total debt | $1.55B | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | |
fin.price_to_book | Price to book value | 20.74× | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm — A ratio our provider could not compute is absent rather than shown as zero. | |
fin.opcf.depth.2026-06-30.operating_cash_flow_m | Operating cash flow — period end 2026-06-30 | −$35.94M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-03-31.operating_cash_flow_m | Operating cash flow — period end 2026-03-31 | $89.36M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-06-30.capex_m | Capital expenditure (reported) — period end 2026-06-30 | −$19.45M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-03-31.capex_m | Capital expenditure (reported) — period end 2026-03-31 | −$36.32M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-12-31.operating_cash_flow_m | Operating cash flow — period end 2025-12-31 | $64.70M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-12-31.capex_m | Capital expenditure (reported) — period end 2025-12-31 | −$63.88M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-09-30.operating_cash_flow_m | Operating cash flow — period end 2025-09-30 | $148.72M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-09-30.capex_m | Capital expenditure (reported) — period end 2025-09-30 | −$57.30M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
earn.pt_range | Analyst price target, low to high | $24.50 – $42.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 5, 2026 · Coverage not supplied | |
earn.pt_consensus | Consensus analyst price target | $32.17 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 5, 2026 · Coverage not supplied | |
earn.pt_median | Median analyst price target | $32.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 5, 2026 · Coverage not supplied | |
own.insiders | Insider transactions via FMP | 60 transactions · 0 purchases, 13 sales, 47 other transactions · 9 identified insiders · of the newest 60 records, those within the last 180 days, newest dated Oct 1, 2026 | FMP | Financial Modeling Prep (FMP), carrying Form 4 transaction records — Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent. | |
own.institutions.depth.ownership_pct | Institutional ownership | 69.3% | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Period end Jun 30, 2026 | |
own.institutions.depth.ownership_pct_previous_quarter | Previous quarter · ownership | 65.4% | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Prior to period end Jun 30, 2026 | |
own.institutions.depth.holders | Reporting holders | 586 | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Period end Jun 30, 2026 | |
own.institutions.depth.holders_previous_quarter | Previous quarter · holders | 490 | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Prior to period end Jun 30, 2026 | |
own.top_holders.depth.holder_0.shares | Blackrock, INC. — shares in provider snapshot | 28,703,514 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_1.shares | Susquehanna International Group, Llp — shares in provider snapshot | 13,539,700 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_2.shares | Vanguard Portfolio Management LLC — shares in provider snapshot | 10,559,314 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_3.shares | Vanguard Capital Management LLC — shares in provider snapshot | 9,541,384 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_4.shares | Susquehanna International Group, Llp — shares in provider snapshot | 9,004,900 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. |
UNRECORDED — 4 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
earn.history | Reported versus estimated, recent quarters | EPS beat 4 of 8 | UNRECORDED | Stored earnings-history observation — Captured 2026-10-04 | |
fin.scores | Distress and quality screens | Altman Z 1.59 · Piotroski F 2 | UNRECORDED | Stored financial-scores observation — Captured 2026-10-04 · Expired observation | |
px.range52 | 52-week range | $13.74 – $65.30 | UNRECORDED | Stored company-profile observation — Captured 2026-10-04 | |
fin.ratios | Return and yield ratios (trailing twelve months) | ROE -30.0% · ROA -3.9% · current ratio 0.93 · earnings yield -2.1% · free-cash-flow yield 1.4% | — | UNRECORDED | Stored key metrics — Date unknown |
COMPUTED — 3 facts from our arithmetic, formula restated
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
fin.mcap_to_cash | Market value per dollar of cash and short-term investments | 7.87× | — | COMPUTED | Computed on this page from the figures above — The market capitalisation printed on this page divided by cash and short-term investments of $841.05M at Jun 30, 2026. Long-term investments are excluded and remain unclassified. Restrictions on cash and short-term investments require separate review. Market cap record date: 2026-10-05. Balance-sheet reference date: 2026-06-30. The inputs do not establish a single common source date for this ratio. |
earn.history.depth.2026-08-10.revenue_actual.comparison | Latest report · revenue vs estimate | Above estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported revenue ($753.21M) with the recorded estimate ($698.90M) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
earn.history.depth.2026-08-10.eps_actual.comparison | Latest report · EPS vs estimate | Below estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported EPS (−$0.3700) with the recorded estimate (−$0.0498) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
OURS — 2 facts from Stock Expert AI's own score and rank
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
ours.moonshot | MoonshotScore v2 | 33 of 100 · Weak · pillars 76 / 8 / 48 / 78 / 44 | OURS | Stock Expert AI MoonshotScore v2 engine | |
ours.moonshot_change | MoonshotScore movement | 33 (stored snapshot Oct 4, 2026) → 33 (current publication computed Oct 5, 2026) (0) | OURS | Stock Expert AI current score publication and immutable score snapshots |
Fact-family notes
- Quarterly statement note. Source series as of 2026-06-30. USD. The operating result is the FMP-standardized value supplied by FMP; it may differ from a filing’s GAAP loss from operations when the provider classifies separately presented items differently. It is not net income or cash flow. Applies to Fact IDs:
fin.q_table.depth.2026-06-30.revenue_k,fin.q_table.depth.2026-06-30.sga_k,fin.q_table.depth.2026-06-30.operating_result_k,fin.q_table.depth.2026-03-31.revenue_k,fin.q_table.depth.2026-03-31.rd_k,fin.q_table.depth.2026-03-31.sga_k,fin.q_table.depth.2026-03-31.operating_result_k,fin.q_table.depth.2025-12-31.revenue_k,fin.q_table.depth.2025-12-31.rd_k,fin.q_table.depth.2025-12-31.sga_k,fin.q_table.depth.2025-12-31.operating_result_k,fin.q_table.depth.2025-09-30.revenue_k,fin.q_table.depth.2025-09-30.rd_k,fin.q_table.depth.2025-09-30.sga_k,fin.q_table.depth.2025-09-30.operating_result_k. - Earnings-history note. Source series as of 2026-08-10. Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined. Applies to Fact IDs:
earn.history.depth.2026-08-10.revenue_actual,earn.history.depth.2026-08-10.revenue_estimated,earn.history.depth.2026-08-10.revenue_actual.comparison,earn.history.depth.2026-08-10.eps_actual.comparison,earn.history.depth.2026-08-10.eps_actual,earn.history.depth.2026-08-10.eps_estimated,earn.history.depth.2026-05-11.revenue_actual,earn.history.depth.2026-05-11.revenue_estimated,earn.history.depth.2026-05-11.eps_actual,earn.history.depth.2026-05-11.eps_estimated,earn.history.depth.2026-02-23.revenue_actual,earn.history.depth.2026-02-23.revenue_estimated,earn.history.depth.2026-02-23.eps_actual,earn.history.depth.2026-02-23.eps_estimated,earn.history.depth.2025-11-03.revenue_actual,earn.history.depth.2025-11-03.revenue_estimated,earn.history.depth.2025-11-03.eps_actual,earn.history.depth.2025-11-03.eps_estimated. - Cash-flow note. Source series as of 2026-06-30. USD. Negative operating cash flow means cash used. Capital expenditure keeps the provider’s reported sign; it is not added here to estimate free cash flow or runway. Applies to Fact IDs:
fin.opcf.depth.2026-06-30.operating_cash_flow_m,fin.opcf.depth.2026-03-31.operating_cash_flow_m,fin.opcf.depth.2026-06-30.capex_m,fin.opcf.depth.2026-03-31.capex_m,fin.opcf.depth.2025-12-31.operating_cash_flow_m,fin.opcf.depth.2025-12-31.capex_m,fin.opcf.depth.2025-09-30.operating_cash_flow_m,fin.opcf.depth.2025-09-30.capex_m.
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources used for research written 2026-09-13
Historical evidence preserved with this analysis. Current figures are listed separately above.
| Evidence | Captured value | Source date | Source type | Source |
|---|---|---|---|---|
| Business description | Hims & Hers Health, Inc. operates a comprehensive digital health platform that seamlessly links individuals with licensed medical professionals for virtual consultations and ongoing care. Through its user-friendly websites and mobile app, the company delivers a diverse portfolio of health and wellness solutions directly to consumers. This includes access to recurring prescription medications, alongside a wide selection of over-the-counter drugs, devices, cosmetics, and dietary supplements. Its core focus areas are general wellness, sexual health, skincare, and hair care. Specific non-prescription offerings span categories such as: Wellness: encompassing items like vitamin C, melatonin, biotin, and collagen protein supplements. Skincare: including products such as moisturizers, serums, and face washes. Sexual Health: providing essentials like condoms, climax delay sprays and wipes, vibrators, and lubricants. Hair Care: offering specialized shampoos, conditioners, scalp scrubs, and topical treatments like minoxidil. Beyond direct sales, Hims & Hers also distributes health and wellness products via wholesale partnerships. The company's headquarters are located in San Francisco, California. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) company profile |
| Quarterly income statement (USD thousands) | Captured record · 8 entries
| 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements |
| Annual revenue and net result (USD millions) | Captured record · 5 entries
| 2025-12-31 | FMP | Financial Modeling Prep (FMP), from the company's 10-K income statements |
| Cash, investments and debt | Total debt: $1.55B; Liquidity basis: cash and short-term investments; Total liabilities: $3.30B; Cash and short-term investments: $841.05M; Cash and investments: $841.00M; Long-term investments: $0; Long-term investments classification: unclassified Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's balance sheet |
| Reported versus estimated, last 8 quarters | Captured record · 8 entries
| 2026-08-10 | FMP | Financial Modeling Prep (FMP) earnings |
| Trailing twelve-month ratio set | Quick ratio: 0.87; Current ratio: 0.93; Debt to equity: 4.77; Net margin: -5.5%; Gross margin: 64.7%; Operating margin: -3.6%; Return on assets: -3.9%; Return on equity: -30% Price-based multiples captured at research time are not repeated here; the page shows each once, from current figures with their own dates. A ratio our provider could not compute is absent rather than shown as zero. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm |
| Cash and investment components | Total basis: cash short and long-term investments; Total: $841.00M; Cash and short-term investments: $841.00M; Long-term investments: $0; Long-term investments classification: unclassified Sums the balance sheet's cash and short-term investments with its long-term investments.; The long-term investment field does not establish marketability; the sum is not a measure of available liquidity.; These provider fields do not establish investment access restrictions or explain differences from third-party cash figures. | 2026-06-30 | COMPUTED | Computed from the balance sheet |
| Distress and quality screens | Altman Z-score: 1.53; Piotroski F-score: 2 Altman Z below 1.8 is the conventional distress zone. The screen is built for manufacturers and industrials; for banks, insurers and property companies it is not a meaningful reading. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) financial scores |
| Insider transactions, last 180 days | Net shares: -1,857,090; Window days: 180; Price low: $5.01; Clustered days: 2026-08-14; Price high: $35.09; Buy transactions: 0; Distinct insiders: 10; Sell transactions: 6; Other transactions: 54; Total transactions: 60; Other transaction types: G-Gift: 1, J-Other: 1, F-InKind: 7, M-Exempt: 45; Unknown direction transactions: 0 Purchase and sale counts require explicit provider transaction types, without a conflicting acquisition/disposition direction. Other transactions retain their provider type; awards, exercises, gifts and in-kind transactions are not counted as purchases or sales. Net shares sums acquired minus disposed shares across direction-known records, including other transaction types; unknown directions are excluded. It is not net purchases or a verified change in beneficial ownership. Named-insider counts, same-day clusters and positive reported prices cover all retained records. Filing dates are used only when transaction dates are absent. Neither timing nor price establishes motive or whether a transaction was on the open market. | 2026-09-02 | FMP | Financial Modeling Prep (FMP) insider transactions, from Form 4 filings |
| Next earnings report | Date: 2026-11-09; EPS estimate: $0.08 per share; Revenue estimate: $892.62M The date is our provider's estimate until the company confirms it. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) earnings calendar |
| Named officers | CEO: Andrew Dudum; Officers: Irene A. Becklund — Title: Chief Accounting Officer, Pay: $361,125, Born: 1984; Kathryn H. Beiser — Title: Chief Communications Officer; Patrick Carroll — Title: Global Chief Medical Officer, Pay: $40,000, Born: 1958; Sarah Stuart — Title: Senior Vice President of People; Soleil Teubner Boughton — Title: Chief Legal Officer & Corporate Secretary, Pay: $772,440, Born: 1978; Andrew Dudum — Title: Co-Founder, Chairman & Chief Executive Officer, Pay: $1.32M, Born: 1988; Mike Chi — Title: Chief Operating Officer, Pay: $828,914, Born: 1980; Mohamed ElShenawy — Title: Chief Technology Officer, Pay: $3.65M, Born: 1975 Titles and pay come from the company's proxy statement as our provider parsed it. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) key executives (proxy-derived) |
| Largest 5 institutional holders | Captured record · 5 entries
| 2026-06-30 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings |
| Operating cash flow by quarter (USD millions) | Captured record · 8 entries
| 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements |
Data provided for informational purposes only.